Efgartigimod alfa and Hyaluronidase-qvfc - An Overview

Overview:

Efgartigimod alfa and Hyaluronidase-qvfc are used to treat two conditions in adults such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). In gMG, it helps improve muscle strength by blocking a protein that causes damage to receptors needed for muscle contraction. For CIDP, it slows down the worsening of symptoms by affecting how the immune system attacks nerve insulation. The medication is given under the skin and includes a component that helps it spread effectively. It was approved by the United States Food and Drug Administration (USFDA) on June 21st, 2024.

Drug Group:

Efgartigimod alfa is a neonatal Fc receptor blocker that blocks a protein to treat muscle weakness with specific antibodies.

Available Doses and Dosage Forms:

Since Efgartigimod alfa and Hyaluronidase-qvfc can temporarily lower IgG (Immunoglobulin G) levels, it is not recommended to get live vaccines while being treated with this medication. Before starting a new treatment cycle, it is important to check if any age-appropriate vaccinations are needed according to the guidelines.

• Efgartigimod alfa and Hyaluronidase-qvfc should only be given by a healthcare professional.

• It is for subcutaneous use only (medication should be injected into the fatty tissue just beneath the skin) using a winged infusion set. Do not give it through into the vein or the vein.

• Do not dilute the medication.

• The recommended dose is 1,008 milligrams or mg (1,008 mg of Efgartigimod alfa and 11,200 units of hyaluronidase) given under the skin over 30 to 90 seconds, once a week for four weeks.

For Patients:

What Is Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune condition where the body mistakenly targets its own tissues. Specifically, in CIDP, the immune system attacks the myelin sheaths, which are the protective coverings around nerve fibers that help them transmit signals effectively.

How Does Efgartigimod alfa and Hyaluronidase-qvfc Work?

Efgartigimod alfa is a type of antibody that attaches to a specific receptor in the body, causing a decrease in a certain type of protein called IgG that circulates in the blood. Hyaluronidase, on the other hand, makes it easier for fluids to pass through tissues under the skin by breaking down a substance called hyaluronan.

What Is the Dosage of Efgartigimod alfa and Hyaluronidase-qvfc?

Efgartigimod alfa and Hyaluronidase-qvfc are combined in a solution for injection under the skin, containing 1,008 milligrams of Efgartigimod and 11,200 units of Hyaluronidase in a total volume of 5.6 milliliters, with concentrations of 180 milligrams per milliliter for Efgartigimod and 2,000 units per milliliter for hyaluronidase.

What Are the Things to Inform the Doctor Before Taking the Efgartigimod alfa and Hyaluronidase-qvfc?

• Inform the doctor and pharmacist if allergic to Efgartigimod alfa-fcab, any other medications, or any ingredients in the injection.

• Ask the pharmacist for a list of ingredients. Let them know about all the prescription and nonprescription medications, vitamins, supplements, and herbal products that are currently taking or planning to take, as the doctor may need to adjust the doses or monitor for side effects.

• Tell the doctor if having an infection, have had recurring infections, or have any other medical conditions.

• Inform them if pregnant, planning to become pregnant, or breastfeeding. If the patient becomes pregnant while on this medication, contact the doctor.

• Avoid getting any vaccinations without consulting the doctor.

How Is Efgartigimod alfa and Hyaluronidase-qvfc Administered?

• A specific type of needle setup (a winged infusion set) is used with a tube that is 12 inches long.

• The transfer needle should be taken off the syringe, and the syringe should be attached to the winged infusion set.

• Before giving the medicine, gently push the syringe plunger until it reaches 5.6 mL (milliliter), ensuring there is medicine at the end of the needle.

• Pick an injection spot on the belly that is at least two to three inches away from the belly button. Avoid injecting into red, bruised, tender, hard areas or where there are moles or scars.

• Change the injection spot each time the medicine is given.

• Pinch the skin and inject the medicine at a 45-degree angle over 30 to 90 seconds.

• An individual might react at the injection site after giving the medicine.

• Throw away any leftover medicine, the syringe, and the winged infusion set after use.

• Healthcare professionals should watch for any allergic reactions for at least 30 minutes after giving the medicine. If any allergic reaction happens, they should take appropriate actions or the patient should seek medical help.

What Are the Side Effects of Efgartigimod alfa and Hyaluronidase-qvfc?

• Infections: Using Efgartigimod alfa and Hyaluronidase-qvfc can increase infection risk. Common infections include respiratory and urinary tract infections (UTI).

• Hypersensitivity Reactions: Some patients may experience allergic reactions like rash, swelling, or difficulty breathing.

• Infusion-Related Reactions: Reactions like itching or flushing may occur during or after the infusion process.

Missed Dose:

If a dose is missed, it can be given within three days of the scheduled time, and then continue with the regular injection schedule.

Overdose:

Inform the doctor if Efgartigimod alfa and Hyaluronidase-qvfc are taken more than indicated accompanied by passing out or breathing difficulties.

Storage:

Efgartigimod alfa and Hyaluronidase-qvfc is a subcutaneous injection containing. It comes as a clear to slightly cloudy yellowish solution in a single-use vial. Each vial contains 1,008 mg of Efgartigimod alfa and 11,200 units of Hyaluronidase in 5.6 mL. Store the vials in their original packaging in a refrigerator at 36 to 46 degrees Fahrenheit (two to eight degrees Celsius) to protect them from light. Do not freeze or shake the vials. If necessary, unopened vials can be kept at room temperature (68 to 77 degrees Fahrenheit or 20 to 25 degrees Celsius) for up to three days once, then returned to the refrigerator. Mark the dates when the vial is removed from and returned to the refrigerator on the carton.

For Doctors:

Indication:

Efgartigimod alfa and Hyaluronidase-qvfc are medications that are used to treat adults who have certain muscle and nerve disorders, such as generalized myasthenia gravis (gMG) where they test positive for anti-acetylcholine receptor (AChR) antibodies, and chronic inflammatory demyelinating polyneuropathy (CIDP).

Dose:

The injection contains 1,008 mg of Efgartigimod alfa and 11,200 units of Hyaluronidase in a 5.6 mL vial (180 mg and 2,000 units per mL). It comes as a yellowish, clear to slightly cloudy solution in a single-use vial.

Dosing Considerations:

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): For CIDP, the dose is the same (1,008 mg per 11,200 units) given subcutaneously once a week over 30 to 90 seconds.

What Are the Pharmacological Aspects of Efgartigimod alfa and Hyaluronidase-qvfc?

• Pharmacodynamics:

  • In study 1, Efgartigimod-alfa Hyaluronidase-fcab was given intravenously to patients who tested positive for AChR antibodies. It was found that this treatment reduced the levels of total IgG in the blood and also decreased the levels of AChR autoantibodies. Patients who had a decrease in AChR autoantibodies showed improvement in their clinical symptoms as measured by changes in the MG-ADL total score.

  • In Study 2 comparative effects of Efgartigimod alfa and Hyaluronidase-qvfc, given as a subcutaneous injection, with Efgartigimod alfa-fcab given intravenously (EFG IV) in patients with gMG. Both treatments showed similar maximum reductions in AChR antibody levels by week four, with Efgartigimod alfa and Hyaluronidase-qvfc achieving a mean reduction of 62.2 percent and EFG IV a reduction of 59.7 percent. The decrease in total IgG levels followed a similar pattern. Statistical analysis showed that there was no significant difference between the two formulations in reducing AChR antibodies over the first four weeks of treatment.

• Mechanism of Action: Efgartigimod alfa is a fragment of a human antibody that attaches to a receptor in the body called the neonatal Fc receptor (FcRn). By binding to FcRn, Efgartigimod alfa reduces the levels of certain antibodies (IgG) circulating in the blood. Whereas Hyaluronidase substance increases the permeability (ability to pass through) of the tissue under the skin by breaking down hyaluronan, which is a part of the tissue structure. This effect is temporary, lasting for 24 to 48 hours, after which the tissue returns to its normal state.

• Pharmacokinetics: The exposure to Efgartigimod alfa increases in proportion to the dose of Efgartigimod alfa and Hyaluronidase-qvfc highest subcutaneous dose tested, which was 1750 mg (1.75 times the recommended dose). The volume of distribution of Efgartigimod alfa is estimated to be between 15 to 20 liters in the body. Metabolism and elimination of Efgartigimod alfa and Hyaluronidase-qvfc are broken down by enzymes in the body into smaller peptides and amino acids. The time it takes for half of the efgartigimod alfa to be cleared from the body (terminal half-life) ranges from 80 to 120 hours (three to five days).

Toxicity:

There have been no studies to determine if Efgartigimod alfa can cause cancer or genetic changes. Similar studies have not been conducted for the hyaluronidase component. In rats, Efgartigimod alfa did not affect fertility when given at doses much higher than those used in humans. In monkeys, no reproductive effects were seen with hyaluronidase at doses significantly higher than those used in humans. These findings suggest that Efgartigimod alfa and Hyaluronidase are not expected to affect cancer risk, genetic makeup, or fertility in humans based on current animal studies.

Clinical Studies:

In clinical studies, Efgartigimod alfa and Hyaluronidase-qvfc, CIPD study involved two stages. In the first stage, patients with CIDP received weekly injections of Efgartigimod alfa and Hyaluronidase-qvfc until they showed improvement. Those who responded entered the second stage, where they were randomly assigned to continue receiving Efgartigimod alfa and Hyaluronidase-qvfc or a placebo. Patients who received Efgartigimod alfa and Hyaluronidase-qvfc experienced a significant delay in disease progression compared to those who received a placebo, as measured by the INCAT (inflammatory neuropathy cause and treatment) disability score.

Warnings and Precautions:

1. Infections:

• Efgartigimod alfa and Hyaluronidase-qvfc may increase the risk of infections.

• In a study, common infections included urinary tract infections (ten percent in treated patients vs. five percent in those given a placebo) and respiratory tract infections (33 percent vs. 29 percent).

• More treated patients had low white blood cell counts (12 percent vs. five percent), low lymphocyte counts (28 percent vs. 19 percent), and low neutrophil counts (13 percent vs. six percent) compared to those on a placebo.

• Most infections and blood abnormalities were mild to moderate.

• Delay Efgartigimod alfa and Hyaluronidase-qvfc if the patient has an active infection until it resolves.

• Monitor for signs of infections during treatment. If a serious infection occurs, treat it appropriately and consider stopping Efgartigimod alfa and Hyaluronidase-qvfc until the infection clears up.

2. Immunization:

• Vaccination safety during Efgartigimod alfa and Hyaluronidase-qvfc treatment has not been studied.

• The safety of live or live-attenuated vaccines and the response to any vaccine are unknown.

• Since Efgartigimod alfa and Hyaluronidase-qvfc lower IgG levels, avoid live or live-attenuated vaccines during treatment.

• Before starting a new treatment cycle, check if the patient needs any age-appropriate vaccines according to guidelines.

3. Hypersensitivity Reactions:

• Reactions like rash, swelling, and breathing difficulties were seen in patients treated with Efgartigimod alfa and Hyaluronidase-qvfc. Hives were also observed.

• In clinical trials, these reactions were mild to moderate, occurred within one hour to three weeks after administration, and did not stop the treatment.

• Healthcare professionals should watch for signs of hypersensitivity reactions for at least 30 minutes after administration. If a reaction occurs, they should take appropriate actions, or the patient should seek medical attention.

What Are the Drug Interactions of Efgartigimod alfa and Hyaluronidase-qvfc?

Using Efgartigimod alfa and Hyaluronidase-qvfc with medications that also bind to the human neonatal Fc receptor (FcRn), like certain immunoglobulin products or monoclonal antibodies containing the IgG subclass, may decrease how well these medications work. Monitor closely for reduced effectiveness. If long-term use of these medications is necessary, consider stopping Efgartigimod alfa and Hyaluronidase-qvfc and using other treatments instead.

Specific Considerations:

1. Pregnancy: There is no data on the use of Efgartigimod alfa and Hyaluronidase-qvfc or Efgartigimod alfa during pregnancy. Studies in animals showed no harmful effects on fetal development at doses much higher than those used in humans. Antibodies like Efgartigimod alfa can pass from mother to fetus, potentially reducing passive immunity in newborns. Consider risks versus benefits before giving live vaccines to babies exposed to Efgartigimod alfa and Hyaluronidase-qvfc in the womb.

2. Lactation: It is unknown if Efgartigimod alfa and Hyaluronidase-qvfc from Efgartigimod alfa and Hyaluronidase-qvfc are present in human milk or their effects on infants. Maternal antibodies are typically found in breast milk. Balance the benefits of breastfeeding with the need for Efgartigimod alfa and Hyaluronidase-qvfc and potential risks to the nursing infant.

3. Pediatric Use: Safety and effectiveness in children have not been established.

4. Geriatric Use: Studies did not include enough elderly patients to determine if they respond differently to Efgartigimod alfa and Hyaluronidase-qvfc.

5. Renal Impairment: No dosage adjustment is needed for mild renal impairment. More data is needed for moderate and severe impairment to understand Efgartigimod alfa and Hyaluronidase-qvfc's effects.